We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.00 | 9.00 | 9.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.34 | 52.55M |
TIDMETX
RNS Number : 4183G
e-Therapeutics plc
18 July 2023
e-therapeutics plc
("e-therapeutics" or the "Company")
Result of Annual General Meeting
London, UK, 18 July 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that at its Annual General Meeting held earlier today, all resolutions, as set out in the Notice of Meeting, were duly passed.
The votes were as follows:
Resolution Votes For % Votes % Abstentions Resolution Against Result Ordinary Resolution 1 370,258,508 100 0 0 0 Passed ------------ ----- --------- ------ ------------ ----------- Ordinary Resolution 2 370,250,879 99.9 3,463 0.001 4,166 Passed ------------ ----- --------- ------ ------------ ----------- Ordinary Resolution 3 370,250,879 99.9 3,463 0.001 4,166 Passed ------------ ----- --------- ------ ------------ ----------- Ordinary Resolution 4 370,255,045 99.9 3,463 0.001 0 Passed ------------ ----- --------- ------ ------------ ----------- Ordinary Resolution 5 370,196,546 99.9 38,462 0.010 23,500 Passed ------------ ----- --------- ------ ------------ ----------- Special Resolution 6 370,195,129 99.9 39,879 0.011 23,500 Passed ------------ ----- --------- ------ ------------ -----------
Enquiries:
e-therapeutics plc Ali Mortazavi, CEO Tel: +44 (0)20 4551 Timothy Bretherton, Director of Finance 8888 and Operations www.etherapeutics.co.uk ------------------------------------------------ ------------------------- SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470 Nominated Adviser and Broker Matthew Johnson/Harry Davies-Ball (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) ------------------------------------------------ -------------------------
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary HepNetTM platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetTM. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicTM constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGRPMATMTBBBLJ
(END) Dow Jones Newswires
July 18, 2023 11:20 ET (15:20 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions